6076 BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection

Wong, Rachel; Saffery, Claire; Barbáchano, Yolanda; Chau, Ian; Valle, Juan W; Hickish, Tamas; Mudan, Satvinder; Khan, Aamir Z.; Chua, Yu Jo; Cunningham, David

doi:10.1016/s1359-6349(09)71171-1

Cited by 15 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the subset of patients with metastases limited to the liver, 12.3% of patients receiving chemotherapy plus bevacizumab (26 of 211) eventually received a R0 resection, compared with 11.6% of patients (24 of 207) treated with chemotherapy plus placebo (p ϭ .81). Additional phase II studies and case series have evaluated preoperative bevacizumab with chemotherapy for patients with liver-only disease, with encouraging rates of conversion to resectability (Table 3) [61,63,64]. Practice patterns for the use of preoperative bevacizumab vary.…”

Section: Bevacizumab and Resection Of Metastatic Disease With Curativmentioning

confidence: 99%

Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

Strickler

Hurwitz

2012

The Oncologist

View full text Add to dashboard Cite

Since its approval for the first‐line treatment of metastatic colorectal cancer (mCRC), bevacizumab has become a standard treatment option in combination with chemotherapy for patients with mCRC. Bevacizumab has demonstrated efficacy in combination with a number of different backbone chemotherapy regimens, and its widespread use has introduced several important questions regarding the selection and optimization of bevacizumab‐based treatment regimens, its use in various patient populations, and the identification of associated adverse events. This review discusses the results of several phase II and phase III clinical trials, as well as large observational studies, to address the use of bevacizumab in the treatment of patients with mCRC in the first‐line setting.

show abstract

Section: Bevacizumab and Resection Of Metastatic Disease With Curativmentioning

confidence: 99%

Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

Strickler

Hurwitz

2012

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Percentage of operability achieved in our study is comparable to the results of analysis mentioned above. Additional studies have assessed conversion therapy with bevacizumab in patients with liveronly metastases, with encouraging results [46,47,48].…”

Section: Discussionmentioning

confidence: 99%

Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma

Ušáková

Sevcikova²,

Usak³

et al. 2012

neo

View full text Add to dashboard Cite

Colorectal carcinoma (CRC) is a malignancy of worldwide increased incidence. The vast majority of all CRC cases occur in patients older than age 50. The initial stage at the time of diagnosis has a strong influence on the overall survival (OS). According to AJCC sixth edition system, 5-year stage-specific survivals are over 90% in stage I, but only approximately 8% in stage IV [1]. Chemotherapy in combination with biological treatment has improved response rates (RR), with prolongation of progression free survival (PFS) and OS. Important role in treatment of metastatic colorectal carcinoma (mCRC) plays surgical resection of metastases. Multidisciplinary cooperation between medical oncologist, surgeon, radiologist and radiotherapist is necessary to achieve the best therapeutic results. The aim of our analysis was to describe the efficacy of bevacizumab used in combination with chemotherapy in the first-line setting and to evaluate frequency of thromboembolic complications during the treatment. The analysis included 58 patients with mCRC, who have been treated with first-line chemotherapy in combination with bevacizumab at the St. Elizabeth Cancer Institute in Bratislava since 2006 and first assessed for the first therapeutic results in October 2010. The clinical benefit after the treatment represented by overall response rate (ORR) and stable disease (SD) was achieved in 87.93% of patients, and surgical resection of metastases after therapy underwent 12.07% of patients. Median time to progression (TTP) was 8 months and median OS evaluated in October 2011 was 27 months. Mutation status of KRAS gene had no influence on the effectiveness of treatment and BRAF mutations exhibited a strong negative prognostic significance. Thromboembolic complications were present in 17.24%.

show abstract

“…Despite a high recurrence rate, 5‐year survival rate up to 38% can be observed in patients with initially unresectable metastases that become resectable after chemotherapy 14–17. The conversion of unresectable to resectable CLMs is therefore a primary objective of the treatment strategy in these patients and by the way, the resection rate has become an endpoint of clinical trial evaluating new anticancer agents for advanced colorectal cancer 2, 3, 12, 13.…”

Section: The Rationale and Benefits Of Preoperative Chemotherapy In Pmentioning

confidence: 99%

“…Another study with a similar design has evaluated the efficacy of bevacizumab in combination with oxaliplatin based chemotherapy in 46 patients with colorectal liver only metatsases (BOXER trial) 3. It concludes that bevacizumab in association with oxaliplatin‐based chemotherapy is associated with 78% response rate and 32% of conversion of unresectable to resectable CLMs.…”

Section: The Rationale and Benefits Of Preoperative Chemotherapy In Pmentioning

confidence: 99%

See 1 more Smart Citation

Neoadjuvant therapy of colorectal liver metastases: Lessons learned from clinical trials

Brouquet

Nordlinger

2010

Journal of Surgical Oncology

View full text Add to dashboard Cite

Neoadjuvant chemotherapy is increasingly used to improve outcome in patients with colorectal liver metastases (CLM). In patients with unresectable CLM, recent clinical trials evaluate the ability of chemotherapy to increase the resectability rate. In patients with resectable CLM, the objective is to decrease the risk of recurrence after hepatectomy that still remains elevated despite the improvement of the surgical technique. A multidisciplinary approach of patients with CLM is desirable whatever the initial status of resectability.

show abstract

6076 BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection

Cited by 15 publications

References 0 publications

Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma

Neoadjuvant therapy of colorectal liver metastases: Lessons learned from clinical trials

Contact Info

Product

Resources

About